Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?

Duric, V M; Stockler, M R; Heritier, S; Boyle, F; Beith, J; Sullivan, A; Wilcken, N; Coates, A S; Simes, R J

Duric, V M; Stockler, M R; Heritier, S; Boyle, F; Beith, J; Sullivan, A; Wilcken, N; Coates, A S; Simes, R J.

Affiliation

Duric VM; NHMRC Clinical Trials Centre, University of Sydney,Camperdown, NSW 2050, Australia.

Ann Oncol ; 16(11): 1786-94, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16126738

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Patient Satisfaction; Adult; Aged; Breast Neoplasms/psychology; Chemotherapy, Adjuvant; Cyclophosphamide/therapeutic use; Doxorubicin/therapeutic use; Female; Fluorouracil/therapeutic use; Humans; Life Expectancy; Methotrexate/therapeutic use; Middle Aged; Neoadjuvant Therapy; Prognosis; Risk Factors; Surveys and Questionnaires; Survival Rate

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Patient Satisfaction Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspects: Patient_preference Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Year: 2005 Document type: Article

Search on Google

XML

PubMed Links